

## Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165<sup>1</sup>

Rq6 A

ZHANG Xiao-Shi, ZHU Xiao-Feng, GAO Jin-Song<sup>2</sup>, QIAN Chao-Nan, KUANG Zhu-Ji, LIU Zong-Chao, ZENG Yi-Xin<sup>3</sup> (Cancer Center, <sup>2</sup>Da-an Gene Diagnostic Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, China)

**KEY WORDS** endothelial growth factors; endothelium; multiple drug resistance; apoptosis; cytotoxicity; drug therapy; Western blotting; polymerase chain reaction; electrophoresis

### ABSTRACT

**AIM:** To investigate the effect of vascular endothelial growth factor 165 (VEGF<sub>165</sub>) on sensitivity of endothelial cells to anticancer drugs. **METHODS:** Human dermal microvessel endothelial cells (HDMEC) were incubated with anticancer drugs in the presence of VEGF<sub>165</sub>. Survival of endothelial cells was assayed by MTT method. DNA fragments of apoptosis were detected by agarose electrophoresis. Potential mechanisms underlying the effect of VEGF<sub>165</sub> on endothelial cells were investigated with RT-PCR and Western blot analysis. **RESULTS:** VEGF<sub>165</sub> induced the multidrug resistance phenotype of HDMEC to a wide variety of anticancer drugs such as epirubicin, cisplatin, etoposide, mytomyacin C, vincristine, CPT-11, and taxol *in vitro*. This protective effect was partly due to the up-regulation of lung drug resistance protein (LRP) and multidrug resistance-associated protein (MRP), as well as the down-regulation of Bax protein induced by VEGF<sub>165</sub>. **CONCLUSION:** VEGF<sub>165</sub> induced multidrug resistance phenotype of endothelial cells, which implicated the anti-angiogenic effect of anticancer drugs might depend on microenvironment of tumors *in vivo*.

### INTRODUCTION

Growth and metastasis of solid tumors depend on angiogenesis, the process leading to the formation of new blood vessels. Suppression of angiogenesis induces apoptosis of tumor cells *in vivo*. The endothelial cells lining in tumor vessels are normal cells, revealing stable genotype and being exposed to drugs directly. Therefore, targeting endothelial cells is superior to targeting tumor cells theoretically. This concept promoted the research on anti-angiogenic agents such as TNP-470, angiostatin, and endostatin<sup>(1-4)</sup>. Up to now, since inhibitors of angiogenesis are not commercially available for clinical usage, attention has been focused on the anti-angiogenic potential of conventional anticancer drugs<sup>(5)</sup>. Anticancer drugs such as taxol, vincristine, vinblastine, 2-methoxyestradiol, bleomycin, epirubicin, doxorubicin, bripirimine, and linomide have the potential to induce apoptosis of endothelial cells *in vitro* and inhibit angiogenesis *in vivo*<sup>(6-8)</sup>. However, no evidence showed that the anti-angiogenic effect of epirubicin and doxorubicin is involved in the response of chemotherapy in breast cancers<sup>(9)</sup>. More evidence was needed to support the development of cytotoxic agents as angiogenesis inhibitors.

Tumor angiogenesis is under the control of angiogenic growth factors and anti-angiogenic growth factors secreted by tumor cells and stroma cells. Vascular endothelial growth factor (VEGF) plays an important role in this process. VEGF is a poly-functional protein containing at least four isoforms, eg, VEGF<sub>121</sub>, VEGF<sub>165</sub>, VEGF<sub>189</sub>, and VEGF<sub>206</sub>, which stimulate the mitogenesis and motion of endothelial cells (ECs), increase the permeability of microvessels and protect endothelial cells from apoptosis induced by TNF- $\alpha$ <sup>(10)</sup>. In addition, VEGF receptors, flt-1 and KDR, are also expressed in hematopoietic stem cells. VEGF<sub>165</sub> can protect hematopoietic stem cells from apoptosis induced by etopo-

<sup>1</sup> Project supported by National Natural Science Foundation of China (No 39900183) and 211 Projects in Sun Yat-sen University of Medical Sciences (No 98069).

<sup>3</sup> Correspondence to Prof ZHENG Yi-Xin.

Phn 86-20-8776-5368, ext 2889. Fax 86-20-8775-4506.

E-mail yxzeng@gzsums.edu.cn

Received 2000-11-20

Accepted 2001-03-15

side, doxorubicin, and  $\gamma$ -ray radiation<sup>[11,12]</sup>. Enlightened by the protective effect of VEGF<sub>165</sub> on EC and hematopoietic stem cells, this study was designed to testify whether VEGF<sub>165</sub> modify the sensitivity of EC to anticancer drugs.

## MATERIALS AND METHODS

**Drugs and cell line** Commercially available anticancer drugs including epirubicin (Farmitalia Carlo Erba, Milan, Italy), vincristine (Eli Lilly, Indianapolis, USA), mitomycin C (Kyowa Hakko Kogyo, Tokyo, Japan), cisplatin (David Bull Laboratories, Vaudruil, Canada), 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin (CPT-11) (Rhne-Poulenc Rorer, Antony, France), taxol (Bristol-Myers Squibb, New York, USA), and etoposide (Clontech, Palo Alto, USA) were dissolved in tissue culture medium before use. Recombinant human VEGF<sub>165</sub> was obtained from Pepro Tech EC Ltd, London, England. Human dermal microvessel endothelial cells (HDMEC) was prepared as previous description<sup>[13]</sup>. Cells were maintained in MCDB131 (Sigma, St Louis, USA) supplemented with 10 % fetal bovine serum (Gibco BRL, Rockville, USA), VEGF<sub>165</sub> 5  $\mu$ g/L, and antibiotics in a humidified atmosphere containing 5 % carbon dioxide at 37  $^{\circ}$ C.

### Cytotoxicity of anticancer drugs to HDMEC

Drug sensitivity of HDMEC to anticancer drugs was measured by MTT assay. The percentage of inhibition rate was defined as:  $[1 - (\text{absorption of the treated well} / \text{absorption of the control well})] \times 100\%$ . The 50 % inhibitory concentration (IC<sub>50</sub>) was calculated by Bliss software. Cell apoptosis was detected by DNA ladder electrophoresis. All drugs were tested in triplicate wells and the experiments were repeated at least four times.

**Expression of drug resistance-associated genes** The isolation of total RNA (Gibco BRL, Rockville, USA) and RT-PCR analysis followed the standard method. Primers used in this study included 5'-CCCATCATTTGCAATAGCAGG-3' and 5'-GTTCAAACTTCTGCTCCTGA-3' for multidrug resistance gene 1 (MDR-1, 157-bp fragment), 5'-CAGGCCATCCCTCTAGACGAG-3' and 5'-GGTAGCTGACCACACGGGTCT-3' for lung drug resistance protein (LRP, 250-bp fragment), 5'-TGAAGGACTTCGTGTCAGCC-3' and 5'-GTCCATGATGGTGTGAGCC-3' for multidrug resistance-associated protein (MRP, 257-bp fragment), 5'-ACAGGTGGAGGCAAATCTTCG-3' and 5'-GAATGACCTGTTAATCCGTTTCG-3' for breast cancer resistance

protein (BCRP, 253-bp fragment), 5'-ATCCCATCACATCTTCCA-3' and 5'-CCTGCTTACCACITTTCTTG-3' for internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 580-bp fragment). RT-PCR productions were subjected to electrophoresis through 2 % agarose.

**Expression of Bax and Bcl-2 proteins** Western blot analysis was used to examine the expression of Bax and Bcl-2 protein. Nitrocellulose membrane was incubated with polyclonal rabbit antibody against human Bax (1:300) and mouse antibody against human Bcl-2 (1:50) goat antibody (Santa Cruz, USA) respectively. After incubation with horseradish peroxidase-conjugated secondary antibodies, protein bands were visioned with enhanced chemoluminescence kit (Amersham, Piscataway, USA).

## RESULTS

**VEGF<sub>165</sub> increased survival of HDMEC treated with anticancer drugs** In the presence of either 5 or 25  $\mu$ g/L of VEGF<sub>165</sub>, HDMEC was treated with anticancer drugs including epirubicin, cisplatin, etoposide, CPT-11, taxol, vincristine, and mytomycin C for 72 h, respectively. The results revealed that VEGF<sub>165</sub> protected HDMEC from cytotoxicity of these drugs. The protective effect of VEGF<sub>165</sub> varied among them. VEGF<sub>165</sub> showed potent protection of HDMEC from epirubicin, intermediate protection from cisplatin, CPT-11, taxol, and mytomycin C, weak protection from etoposide and vincristine (Tab 1).

Tab 1. Protective effect of VEGF<sub>165</sub> on HDMEC from anticancer drugs.  $n = 4$  independent experiments.  $\bar{x} \pm s$ .

Drug	IC <sub>50</sub> /mg·L <sup>-1</sup>		RR <sup>1)</sup>
	VEGF <sub>165</sub> 5 $\mu$ g·L <sup>-1</sup>	VEGF <sub>165</sub> 25 $\mu$ g·L <sup>-1</sup>	
Epirubicin	0.5 $\pm$ 0.4	9.5 $\pm$ 2.1	19.1
Taxol	1.6 $\pm$ 0.3	7.6 $\pm$ 1.2	4.9
Cisplatin	2.8 $\pm$ 0.7	9.4 $\pm$ 0.6	3.4
CPT-11	6.9 $\pm$ 1.4	21.0 $\pm$ 2.3	3.1
Mytomycin C	2.6 $\pm$ 0.5	6.1 $\pm$ 1.2	3.0
Etoposide	3.4 $\pm$ 0.5	7.7 $\pm$ 1.9	2.2
Vincristine	3.5 $\pm$ 1.5	6.2 $\pm$ 1.4	1.8

1): Relative resistance, the ratio of IC<sub>50</sub> for HDMEC in the presence of VEGF<sub>165</sub> 25  $\mu$ g·L<sup>-1</sup> to IC<sub>50</sub> in the presence of VEGF<sub>165</sub> 5  $\mu$ g·L<sup>-1</sup>.

**VEGF<sub>165</sub> protected HDMEC from apoptosis induced by epirubicin** Since VEGF<sub>165</sub> showed the

most potent protection of HDMEC from cytotoxicity of epirubicin, epirubicin was used to damage HDMEC, to investigate mechanism of the protective effect of VEGF<sub>165</sub>. Results showed that VEGF<sub>165</sub> 25 μg/L prevented HDMEC from apoptosis induced by epirubicin 1 mg/L after 24 h of incubation (Fig 1).

Epirubicin(mg·L <sup>-1</sup> )	0	1	1
VEGF <sub>165</sub> (μg·L <sup>-1</sup> )	5	5	25




Fig 1. Protective effect of VEGF<sub>165</sub> on HDMEC. HDMEC was incubated with epirubicin and VEGF<sub>165</sub> for 24 h. VEGF<sub>165</sub> 25 μg/L protected HDMEC from apoptosis induced by epirubicin 1 mg/L.

**VEGF<sub>165</sub> induced expression of drug resistance genes** In the presence of epirubicin 1 mg/L, HDMEC was incubated with either VEGF<sub>165</sub> 5 or 25 μg/L for 24 h. RT-PCR analysis revealed that VEGF<sub>165</sub> induced expression of LRP and MRP, except for BCRP (Fig 2). In addition, HDMEC constitutively expressed MDR-1 gene, VEGF<sub>165</sub> could not modulate the expression of MDR-1.

**VEGF<sub>165</sub> reduced expression of Bax** In the presence of epirubicin 1 mg/L HDMEC was incubated with either VEGF<sub>165</sub> 5 or 25 μg/L for 24 h. Western blot analysis revealed that expression of Bax protein progressively decreased during the 24-h incubation, although the alteration of Bcl-2 protein was not observed (Fig 3).

## DISCUSSION

This study showed that VEGF<sub>165</sub> induced resistance of EC to diverse anticancer drugs including epirubicin, CPT-11, taxol, vincristine, cisplatin, etoposide, and

Epirubicin(mg·L <sup>-1</sup> )	1	1	1	1
VEGF <sub>165</sub> (μg·L <sup>-1</sup> )	5	0	5	25




Fig 2. Expression of LRP and MRP induced by VEGF<sub>165</sub>. HDMEC was incubated with epirubicin and VEGF<sub>165</sub> for 24 h. VEGF<sub>165</sub> induced the expression of LRP (A) and MRP (B) regardless of the presence of epirubicin.




Fig 3. Effect of VEGF<sub>165</sub> on the expression of Bax protein. HDMEC was incubated with epirubicin and VEGF<sub>165</sub> for 24 h. VEGF<sub>165</sub> progressively inhibited the expression of Bax protein induced by epirubicin.

mytomycin C. Among them VEGF<sub>165</sub> revealed potent protection of HDMEC from epirubicin, intermediate protection from cisplatin, CPT-11, taxol, and mytomycin C, weak protection from etoposide and vincristine.

The mechanism underlying multidrug resistance phenotype of EC induced by VEGF<sub>165</sub> is unknown. One of

the possible mechanism is the expression of drug resistance genes. LRP, MRP, and P-glycoprotein are energy-dependent efflux pumps, their substrates include the anthracyclines, the vica alkaloids, the epipodphyllotoxin, taxols, etc. P-Glycoprotein and MRP are membrane-bound proteins extruding substrates from the inside of cell while LRP plays a role in nucleo-cytoplasmic transport<sup>[14-17]</sup>. HDMEC constitutively expressed MDR-1 gene and VEGF<sub>165</sub> could not modulate its expression, suggesting that the expression of MDR-1 gene was not related to the protective effect of VEGF<sub>165</sub>. However, VEGF<sub>165</sub> induced the expression of MRP and LRP, paralleling to the protective effect of VEGF<sub>165</sub>, which implicated that MRP and LRP were involved in this drug resistance phenotype. It was intriguing that VEGF<sub>165</sub> also protected HDMEC from the cytotoxicity of cisplatin, mitomycin C, and CPT-11, in which MRP and LRP did not relate to their drug resistance phenotype<sup>[18,19]</sup>. So alternative mechanism of drug resistance may exist.

Anticancer agents can induce apoptosis and the ratio of Bax to Bcl-2 is the check point upstream of caspases cascade<sup>[20,21]</sup>. In this study, VEGF<sub>165</sub> decreased the expression of Bax induced by epirubicin, it was conceivable that VEGF<sub>165</sub> modified the ratio of Bax to Bcl-2, diminished the death signal, and then suppressed the toxicity of chemotherapy on HDMEC.

Tumor cells are subjected to chronic and acute hypoxia<sup>[22]</sup>. Chemotherapy would enhance hypoxia of tumor cells<sup>[23]</sup> and then hypoxia hasten expression of VEGF<sup>[24]</sup>, so residual tumor cells up-regulate expression of VEGF during chemotherapy. This study showed evidence that VEGF<sub>165</sub> protected ECs from a wide variety of anticancer drugs *in vitro*, it was reasonable to infer that the anti-angiogenic effect of conventional anticancer drugs might depend on the microenvironment of tumors *in vivo*. To develop angiogenesis inhibitors, it was worthy of researching alternative kind of agents which could circumvent the protective effect of VEGF on endothelium.

## REFERENCES

- Zetter B. Angiogenesis and tumor metastasis. *Annu Rev Med* 1998; 49: 407-24.
- Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma; much more than a new prognostic tool. *J Clin Oncol* 1995; 13: 765-82.
- O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell* 1997; 88: 277-85.
- Lu WJ, Zhang XS, Luo JX, Wei YF. Inhibitory effect of recombinant human angiostatin on xenografts of human nasopharyngeal carcinoma CNE-1. *Chin J Cancer* 2000; 19: 890-2.
- Kerbel RS, Vitoria-Petit A, Klement G, Rak J. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. *Eur J Cancer* 2000; 36: 1248-57.
- Arbiser JL, Panigrahy D, Klauber N, Rupnick M, Flynn E, Udagawa T, et al. The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. *J Am Acad Dermatol* 1999; 40: 925-9.
- Steiner R. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. In: Steiner R, Weisz PB, Langer R, editors. *Angiogenesis: key principle-science, technology, medicine*. Basel: Birkhauser Verlag; 1992. p 449-54.
- Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. *Cancer Res* 1997; 57: 81-6.
- Jacquemier JD, Penault-Llorca FM, Bertucci F, Sun ZZ, Houvenaeghel GF, Geneix JA, et al. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. *J Pathol* 1998; 184: 130-5.
- Spyridopoulos I, Brogi E, Kearney M, Sullivan AB, Cetrulo C, Isner JM, et al. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. *J Mol Cell Cardiol* 1997; 29: 1321-30.
- Katoh O, Tauchi H, Kawaiishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. *Cancer Res* 1995; 55: 5687-92.
- Katoh O, Takahashi T, Oguri T, Kuramoto K, Mihara K, Kobayashi M, et al. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an anti-apoptotic factor. *Cancer Res* 1998; 58: 5565-9.
- Qian CN, Min HQ, Lin HL, Feng GK, Ye YL, Wang LG, et al. Anti-tumor effect of angiogenesis inhibitor TNP-470 on the human nasopharyngeal carcinoma cell line NPC/HK1. *Oncology* 1999; 57: 36-41.
- Krishnamachary N, Center MS. The MRP gene associated with non-p-glycoprotein multidrug resistance encodes 190-kDa membrane bound glycoprotein. *Cancer Res* 1993; 53: 3658.
- Tian H, Pan QC. Modulation of multidrug resistance by three bisbenzyl-isoquinolines in comparison with verapamil. *Acta Pharmacol Sin* 1997; 18: 455-8.
- Fu LW, Pan QC, Huang WL, Yang XP. Reversal of tumor multidrug resistance by 2-phenyl-3-(3',5'-dimorpholinomethyl-4'-hydroxy)-benzoyl-indole (HWL-12). *Acta Pharmacol Sin* 1998; 19: 77-80.
- Fu LW, Pan QC, Liang YJ, Huang HB. Circumvention of

- tumor multidrug resistance by a new annonaceous acetogenin: atemoyacin-B. *Acta Pharmacol Sin* 1999; 20: 435-9.
- 18 Jansen WJM, Hulscher TM, van Ark-Otte J, Giaccone G, Pinedo HM, Boven E. CPT-11 sensitivity in relation to the expression of PL70-glycoprotein and multidrug resistance-associated protein. *Br J Cancer* 1998; 77: 359-65.
- 19 Akiyama S, Chen ZS, Sumizawa T, Furukawa T. Resistance to cisplatin. *Anticancer Drug Des* 1999; 14: 143-51.
- 20 Chao DT, Korsmeyer SJ. Bcl-2 family: regulators of cell death. *Annu Rev Immunol* 1998; 16: 395-419.
- 21 Zhu XF, Zhang XS, Li ZM, Yao YQ, Xie BF, Liu ZC, et al. Apoptosis induced by ceramide in hepatocellular carcinoma Bel 7402 cells. *Acta Pharmacol Sin* 2000; 21: 225-8.
- 22 Teicher BA. Physiologic mechanisms of therapeutic resistance, blood flow and hypoxia. *Hematol Oncol Clin North Am* 1995; 9: 475-506.
- 23 Teicher BA, Holden SA, Ara G, Dupuis NP, Goff D. Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing. *Cancer J Sci Am* 1995; 1: 43.
- 24 Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. *Endocr Rev* 1997; 18: 4-25.

### 血管内皮生长因子 165 诱导人血管内皮细胞多药耐药表型<sup>1</sup>

张晓实, 朱孝峰, 高劲松<sup>2</sup>, 钱朝南, 邝珠玑,

刘宗潮, 曾益新 (中山医科大学肿瘤防治中心,  
<sup>2</sup>达安基因研究中心, 广州 510060, 中国)

**关键词** 内皮生长因子; 内皮; 多种抗药性; 细胞凋亡; 细胞毒性; 药物疗法; 蛋白质印迹; 聚合酶链反应; 电泳

**目的:** 研究血管内皮生长因子 165 (VEGF<sub>165</sub>) 对血管内皮细胞药物敏感性的影响. **方法:** 人真皮微血管内皮细胞(HDMEC)与抗癌药物和 VEGF<sub>165</sub>混合培养, MTT 法分析药敏变化, 琼脂糖电泳检测细胞凋亡, RT-PCR、免疫印迹法分析 HDMEC 产生多药耐药表型的机制. **结果:** VEGF<sub>165</sub>体外诱导 HDMEC 对多种抗癌药物耐药, 如表柔比星、顺铂、足叶乙甙、丝裂霉素 C、长春新碱、CPT-11、泰素等, 其机制与 VEGF<sub>165</sub>诱导 HDMEC 上调表达多药耐药相关蛋白和肺耐药相关蛋白以及下调表达 Bax 蛋白有关. **结论:** VEGF<sub>165</sub>诱导血管内皮细胞的多药耐药表型, 提示化疗时抗癌药物的抗血管生成活性可能取决于肿瘤微环境.

(责任编辑 吴民淑)